Dr Gulley speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the phase I study of M7824 for patients with HPV associated cancers.
He comments on how this could change clinical practice in certain settings and highlights the importance of using novel fusion proteins to target PD-L1.
For more on this study watch Dr Strauss discuss it further with ecancer here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.